Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Impedimed Limited ( (AU:IPD) ).
ImpediMed Limited has appointed Erik Anderson as a director of the company, effective 25 February 2026, as disclosed in an initial director’s interest notice lodged with the ASX. At the time of his appointment, Anderson holds no direct or indirect interests in ImpediMed securities and has no interests in any related contracts, indicating a starting position free of equity ties or contractual entanglements that could affect governance and alignment with existing shareholders.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company that develops and commercialises bioimpedance-based devices for the assessment and monitoring of body fluid status. Its products are primarily used in clinical settings to aid in the diagnosis and management of conditions such as lymphedema and heart failure, targeting hospitals, clinics and specialist healthcare providers.
Average Trading Volume: 5,364,483
Technical Sentiment Signal: Sell
Current Market Cap: A$36.7M
See more data about IPD stock on TipRanks’ Stock Analysis page.